nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—SRC—type 2 diabetes mellitus	0.256	0.803	CbGaD
Ponatinib—CYP3A4—type 2 diabetes mellitus	0.0628	0.197	CbGaD
Ponatinib—ABCB11—Glyburide—type 2 diabetes mellitus	0.0335	0.097	CbGbCtD
Ponatinib—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0229	0.0663	CbGbCtD
Ponatinib—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0183	0.053	CbGbCtD
Ponatinib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0174	0.0504	CbGbCtD
Ponatinib—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.0166	0.048	CbGbCtD
Ponatinib—ABCG2—Glyburide—type 2 diabetes mellitus	0.0159	0.0461	CbGbCtD
Ponatinib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0155	0.0449	CbGbCtD
Ponatinib—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.0153	0.0443	CbGbCtD
Ponatinib—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.0148	0.0427	CbGbCtD
Ponatinib—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0131	0.0378	CbGbCtD
Ponatinib—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.012	0.0348	CbGbCtD
Ponatinib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0112	0.0325	CbGbCtD
Ponatinib—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0106	0.0306	CbGbCtD
Ponatinib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0104	0.0302	CbGbCtD
Ponatinib—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00975	0.0282	CbGbCtD
Ponatinib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0093	0.0269	CbGbCtD
Ponatinib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0085	0.0246	CbGbCtD
Ponatinib—CYP3A5—Losartan—type 2 diabetes mellitus	0.00807	0.0234	CbGbCtD
Ponatinib—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00801	0.0232	CbGbCtD
Ponatinib—CYP2C8—Losartan—type 2 diabetes mellitus	0.00776	0.0225	CbGbCtD
Ponatinib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00771	0.0223	CbGbCtD
Ponatinib—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00768	0.0222	CbGbCtD
Ponatinib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00743	0.0215	CbGbCtD
Ponatinib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00672	0.0195	CbGbCtD
Ponatinib—ABCB1—Glyburide—type 2 diabetes mellitus	0.00574	0.0166	CbGbCtD
Ponatinib—ABCB1—Losartan—type 2 diabetes mellitus	0.00525	0.0152	CbGbCtD
Ponatinib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00509	0.0147	CbGbCtD
Ponatinib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00488	0.0141	CbGbCtD
Ponatinib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00488	0.0141	CbGbCtD
Ponatinib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00462	0.0134	CbGbCtD
Ponatinib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00344	0.00996	CbGbCtD
Ponatinib—PDGFRA—penis—type 2 diabetes mellitus	0.00321	0.056	CbGeAlD
Ponatinib—RET—autonomic nervous system—type 2 diabetes mellitus	0.00317	0.0554	CbGeAlD
Ponatinib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00315	0.00911	CbGbCtD
Ponatinib—KDR—hindlimb—type 2 diabetes mellitus	0.00218	0.0381	CbGeAlD
Ponatinib—TEK—artery—type 2 diabetes mellitus	0.00164	0.0286	CbGeAlD
Ponatinib—FGFR4—nephron tubule—type 2 diabetes mellitus	0.00148	0.0259	CbGeAlD
Ponatinib—SRC—artery—type 2 diabetes mellitus	0.00146	0.0254	CbGeAlD
Ponatinib—TEK—endothelium—type 2 diabetes mellitus	0.00138	0.0242	CbGeAlD
Ponatinib—KDR—artery—type 2 diabetes mellitus	0.00134	0.0234	CbGeAlD
Ponatinib—FGFR4—kidney—type 2 diabetes mellitus	0.0013	0.0227	CbGeAlD
Ponatinib—FGFR4—cortex of kidney—type 2 diabetes mellitus	0.00127	0.0221	CbGeAlD
Ponatinib—SRC—endothelium—type 2 diabetes mellitus	0.00123	0.0215	CbGeAlD
Ponatinib—KDR—endothelium—type 2 diabetes mellitus	0.00113	0.0198	CbGeAlD
Ponatinib—BCR—islet of Langerhans—type 2 diabetes mellitus	0.00109	0.019	CbGeAlD
Ponatinib—KIT—endothelium—type 2 diabetes mellitus	0.001	0.0175	CbGeAlD
Ponatinib—FGFR3—kidney—type 2 diabetes mellitus	0.000888	0.0155	CbGeAlD
Ponatinib—BCR—nephron tubule—type 2 diabetes mellitus	0.000874	0.0153	CbGeAlD
Ponatinib—FGFR3—cortex of kidney—type 2 diabetes mellitus	0.000865	0.0151	CbGeAlD
Ponatinib—FGFR4—liver—type 2 diabetes mellitus	0.000822	0.0144	CbGeAlD
Ponatinib—FLT3—cardiovascular system—type 2 diabetes mellitus	0.00078	0.0136	CbGeAlD
Ponatinib—BCR—cortex of kidney—type 2 diabetes mellitus	0.000748	0.0131	CbGeAlD
Ponatinib—SRC—islet of Langerhans—type 2 diabetes mellitus	0.0007	0.0122	CbGeAlD
Ponatinib—BCR—adipose tissue—type 2 diabetes mellitus	0.000692	0.0121	CbGeAlD
Ponatinib—FGFR1—cortex of kidney—type 2 diabetes mellitus	0.000666	0.0116	CbGeAlD
Ponatinib—FGFR1—adipose tissue—type 2 diabetes mellitus	0.000616	0.0108	CbGeAlD
Ponatinib—RET—kidney—type 2 diabetes mellitus	0.000612	0.0107	CbGeAlD
Ponatinib—SRC—retina—type 2 diabetes mellitus	0.000598	0.0104	CbGeAlD
Ponatinib—FGFR2—cardiovascular system—type 2 diabetes mellitus	0.000594	0.0104	CbGeAlD
Ponatinib—FGFR2—kidney—type 2 diabetes mellitus	0.000581	0.0101	CbGeAlD
Ponatinib—TEK—cardiovascular system—type 2 diabetes mellitus	0.000569	0.00994	CbGeAlD
Ponatinib—LYN—liver—type 2 diabetes mellitus	0.000564	0.00985	CbGeAlD
Ponatinib—FGFR3—liver—type 2 diabetes mellitus	0.000561	0.0098	CbGeAlD
Ponatinib—TEK—kidney—type 2 diabetes mellitus	0.000557	0.00973	CbGeAlD
Ponatinib—TEK—pancreas—type 2 diabetes mellitus	0.000554	0.00966	CbGeAlD
Ponatinib—LCK—adipose tissue—type 2 diabetes mellitus	0.000551	0.00963	CbGeAlD
Ponatinib—KDR—retina—type 2 diabetes mellitus	0.00055	0.00961	CbGeAlD
Ponatinib—TEK—cortex of kidney—type 2 diabetes mellitus	0.000543	0.00948	CbGeAlD
Ponatinib—FGFR2—adipose tissue—type 2 diabetes mellitus	0.000524	0.00915	CbGeAlD
Ponatinib—KDR—nephron tubule—type 2 diabetes mellitus	0.000518	0.00905	CbGeAlD
Ponatinib—PDGFRA—cardiovascular system—type 2 diabetes mellitus	0.000516	0.00901	CbGeAlD
Ponatinib—SRC—cardiovascular system—type 2 diabetes mellitus	0.000506	0.00883	CbGeAlD
Ponatinib—TEK—adipose tissue—type 2 diabetes mellitus	0.000502	0.00877	CbGeAlD
Ponatinib—ABL1—islet of Langerhans—type 2 diabetes mellitus	0.000496	0.00867	CbGeAlD
Ponatinib—SRC—kidney—type 2 diabetes mellitus	0.000495	0.00864	CbGeAlD
Ponatinib—SRC—pancreas—type 2 diabetes mellitus	0.000492	0.00859	CbGeAlD
Ponatinib—BCR—liver—type 2 diabetes mellitus	0.000486	0.00848	CbGeAlD
Ponatinib—FLT3—liver—type 2 diabetes mellitus	0.000482	0.00842	CbGeAlD
Ponatinib—KDR—cardiovascular system—type 2 diabetes mellitus	0.000465	0.00813	CbGeAlD
Ponatinib—KIT—nephron tubule—type 2 diabetes mellitus	0.000459	0.00802	CbGeAlD
Ponatinib—KDR—kidney—type 2 diabetes mellitus	0.000455	0.00795	CbGeAlD
Ponatinib—PDGFRA—adipose tissue—type 2 diabetes mellitus	0.000455	0.00794	CbGeAlD
Ponatinib—SRC—adipose tissue—type 2 diabetes mellitus	0.000446	0.00779	CbGeAlD
Ponatinib—KDR—cortex of kidney—type 2 diabetes mellitus	0.000444	0.00774	CbGeAlD
Ponatinib—FGFR1—liver—type 2 diabetes mellitus	0.000432	0.00754	CbGeAlD
Ponatinib—ABL1—retina—type 2 diabetes mellitus	0.000424	0.00741	CbGeAlD
Ponatinib—KIT—cardiovascular system—type 2 diabetes mellitus	0.000412	0.0072	CbGeAlD
Ponatinib—KDR—adipose tissue—type 2 diabetes mellitus	0.00041	0.00717	CbGeAlD
Ponatinib—KIT—kidney—type 2 diabetes mellitus	0.000404	0.00705	CbGeAlD
Ponatinib—KIT—pancreas—type 2 diabetes mellitus	0.000401	0.007	CbGeAlD
Ponatinib—ABL1—nephron tubule—type 2 diabetes mellitus	0.0004	0.00698	CbGeAlD
Ponatinib—KIT—cortex of kidney—type 2 diabetes mellitus	0.000393	0.00686	CbGeAlD
Ponatinib—LCK—liver—type 2 diabetes mellitus	0.000387	0.00675	CbGeAlD
Ponatinib—ABCB11—liver—type 2 diabetes mellitus	0.000378	0.00659	CbGeAlD
Ponatinib—FGFR2—liver—type 2 diabetes mellitus	0.000367	0.00641	CbGeAlD
Ponatinib—KIT—adipose tissue—type 2 diabetes mellitus	0.000364	0.00635	CbGeAlD
Ponatinib—ABL1—cardiovascular system—type 2 diabetes mellitus	0.000359	0.00627	CbGeAlD
Ponatinib—TEK—liver—type 2 diabetes mellitus	0.000352	0.00615	CbGeAlD
Ponatinib—ABL1—kidney—type 2 diabetes mellitus	0.000351	0.00613	CbGeAlD
Ponatinib—ABL1—pancreas—type 2 diabetes mellitus	0.000349	0.00609	CbGeAlD
Ponatinib—ABL1—cortex of kidney—type 2 diabetes mellitus	0.000342	0.00597	CbGeAlD
Ponatinib—Imatinib—CYP1A2—type 2 diabetes mellitus	0.000336	0.33	CrCbGaD
Ponatinib—PDGFRA—liver—type 2 diabetes mellitus	0.000319	0.00557	CbGeAlD
Ponatinib—ABL1—adipose tissue—type 2 diabetes mellitus	0.000317	0.00553	CbGeAlD
Ponatinib—SRC—liver—type 2 diabetes mellitus	0.000313	0.00546	CbGeAlD
Ponatinib—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000291	0.00507	CbGeAlD
Ponatinib—KDR—liver—type 2 diabetes mellitus	0.000288	0.00503	CbGeAlD
Ponatinib—Nilotinib—CYP3A4—type 2 diabetes mellitus	0.000266	0.262	CrCbGaD
Ponatinib—KIT—liver—type 2 diabetes mellitus	0.000255	0.00445	CbGeAlD
Ponatinib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000252	0.0044	CbGeAlD
Ponatinib—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000234	0.00409	CbGeAlD
Ponatinib—CYP2C8—kidney—type 2 diabetes mellitus	0.000228	0.00398	CbGeAlD
Ponatinib—Imatinib—CYP3A4—type 2 diabetes mellitus	0.000222	0.218	CrCbGaD
Ponatinib—ABL1—liver—type 2 diabetes mellitus	0.000222	0.00388	CbGeAlD
Ponatinib—CYP3A5—kidney—type 2 diabetes mellitus	0.000206	0.00359	CbGeAlD
Ponatinib—CYP3A5—pancreas—type 2 diabetes mellitus	0.000204	0.00357	CbGeAlD
Ponatinib—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.0002	0.0035	CbGeAlD
Ponatinib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.0002	0.00349	CbGeAlD
Ponatinib—Imatinib—ALB—type 2 diabetes mellitus	0.000194	0.19	CrCbGaD
Ponatinib—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000185	0.00324	CbGeAlD
Ponatinib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000154	0.0027	CbGeAlD
Ponatinib—CYP3A4—kidney—type 2 diabetes mellitus	0.000154	0.00269	CbGeAlD
Ponatinib—CYP2D6—kidney—type 2 diabetes mellitus	0.000152	0.00265	CbGeAlD
Ponatinib—CYP2C8—liver—type 2 diabetes mellitus	0.000144	0.00251	CbGeAlD
Ponatinib—ABCG2—liver—type 2 diabetes mellitus	0.00014	0.00244	CbGeAlD
Ponatinib—ABCB1—retina—type 2 diabetes mellitus	0.000132	0.0023	CbGeAlD
Ponatinib—CYP3A5—liver—type 2 diabetes mellitus	0.00013	0.00227	CbGeAlD
Ponatinib—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000124	0.00217	CbGeAlD
Ponatinib—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000112	0.00195	CbGeAlD
Ponatinib—ABCB1—kidney—type 2 diabetes mellitus	0.000109	0.00191	CbGeAlD
Ponatinib—ABCB1—pancreas—type 2 diabetes mellitus	0.000109	0.00189	CbGeAlD
Ponatinib—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000106	0.00186	CbGeAlD
Ponatinib—ABCB1—adipose tissue—type 2 diabetes mellitus	9.85e-05	0.00172	CbGeAlD
Ponatinib—CYP3A4—liver—type 2 diabetes mellitus	9.75e-05	0.0017	CbGeAlD
Ponatinib—CYP2D6—liver—type 2 diabetes mellitus	9.6e-05	0.00168	CbGeAlD
Ponatinib—Oedema—Valsartan—type 2 diabetes mellitus	8.55e-05	0.000595	CcSEcCtD
Ponatinib—Dizziness—Pioglitazone—type 2 diabetes mellitus	8.53e-05	0.000594	CcSEcCtD
Ponatinib—Infection—Valsartan—type 2 diabetes mellitus	8.49e-05	0.000591	CcSEcCtD
Ponatinib—Rash—Glipizide—type 2 diabetes mellitus	8.49e-05	0.000591	CcSEcCtD
Ponatinib—Vision blurred—Irbesartan—type 2 diabetes mellitus	8.48e-05	0.000591	CcSEcCtD
Ponatinib—Dermatitis—Glipizide—type 2 diabetes mellitus	8.48e-05	0.000591	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	8.48e-05	0.00059	CcSEcCtD
Ponatinib—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	8.47e-05	0.00059	CcSEcCtD
Ponatinib—Erythema—Losartan—type 2 diabetes mellitus	8.47e-05	0.00059	CcSEcCtD
Ponatinib—Oedema—Orlistat—type 2 diabetes mellitus	8.45e-05	0.000588	CcSEcCtD
Ponatinib—Headache—Glipizide—type 2 diabetes mellitus	8.44e-05	0.000587	CcSEcCtD
Ponatinib—Insomnia—Gliclazide—type 2 diabetes mellitus	8.42e-05	0.000586	CcSEcCtD
Ponatinib—Infection—Orlistat—type 2 diabetes mellitus	8.39e-05	0.000584	CcSEcCtD
Ponatinib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	8.38e-05	0.000584	CcSEcCtD
Ponatinib—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	8.37e-05	0.000583	CcSEcCtD
Ponatinib—Paraesthesia—Gliclazide—type 2 diabetes mellitus	8.36e-05	0.000582	CcSEcCtD
Ponatinib—Anaemia—Irbesartan—type 2 diabetes mellitus	8.32e-05	0.000579	CcSEcCtD
Ponatinib—Dizziness—Glimepiride—type 2 diabetes mellitus	8.31e-05	0.000579	CcSEcCtD
Ponatinib—Skin disorder—Valsartan—type 2 diabetes mellitus	8.3e-05	0.000578	CcSEcCtD
Ponatinib—Dyspnoea—Gliclazide—type 2 diabetes mellitus	8.3e-05	0.000578	CcSEcCtD
Ponatinib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	8.28e-05	0.000577	CcSEcCtD
Ponatinib—Dizziness—Sitagliptin—type 2 diabetes mellitus	8.28e-05	0.000577	CcSEcCtD
Ponatinib—Hypertension—Metformin—type 2 diabetes mellitus	8.24e-05	0.000574	CcSEcCtD
Ponatinib—Oedema peripheral—Ramipril—type 2 diabetes mellitus	8.22e-05	0.000572	CcSEcCtD
Ponatinib—Skin disorder—Orlistat—type 2 diabetes mellitus	8.21e-05	0.000571	CcSEcCtD
Ponatinib—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	8.2e-05	0.000571	CcSEcCtD
Ponatinib—Back pain—Losartan—type 2 diabetes mellitus	8.2e-05	0.000571	CcSEcCtD
Ponatinib—Abdominal pain—Glyburide—type 2 diabetes mellitus	8.19e-05	0.000571	CcSEcCtD
Ponatinib—Dyspepsia—Gliclazide—type 2 diabetes mellitus	8.19e-05	0.00057	CcSEcCtD
Ponatinib—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	8.17e-05	0.000569	CcSEcCtD
Ponatinib—Muscle spasms—Losartan—type 2 diabetes mellitus	8.15e-05	0.000567	CcSEcCtD
Ponatinib—Asthenia—Bromocriptine—type 2 diabetes mellitus	8.13e-05	0.000566	CcSEcCtD
Ponatinib—Myalgia—Metformin—type 2 diabetes mellitus	8.12e-05	0.000566	CcSEcCtD
Ponatinib—Headache—Pioglitazone—type 2 diabetes mellitus	8.08e-05	0.000563	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	8.07e-05	0.000562	CcSEcCtD
Ponatinib—Leukopenia—Irbesartan—type 2 diabetes mellitus	8.06e-05	0.000561	CcSEcCtD
Ponatinib—Visual impairment—Ramipril—type 2 diabetes mellitus	8.04e-05	0.00056	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	8.03e-05	0.000559	CcSEcCtD
Ponatinib—Fatigue—Gliclazide—type 2 diabetes mellitus	8.02e-05	0.000559	CcSEcCtD
Ponatinib—Nausea—Glipizide—type 2 diabetes mellitus	8e-05	0.000557	CcSEcCtD
Ponatinib—Vomiting—Glimepiride—type 2 diabetes mellitus	7.99e-05	0.000556	CcSEcCtD
Ponatinib—Vision blurred—Losartan—type 2 diabetes mellitus	7.98e-05	0.000556	CcSEcCtD
Ponatinib—Vomiting—Sitagliptin—type 2 diabetes mellitus	7.96e-05	0.000555	CcSEcCtD
Ponatinib—Pain—Gliclazide—type 2 diabetes mellitus	7.96e-05	0.000554	CcSEcCtD
Ponatinib—Constipation—Gliclazide—type 2 diabetes mellitus	7.96e-05	0.000554	CcSEcCtD
Ponatinib—Rash—Glimepiride—type 2 diabetes mellitus	7.92e-05	0.000552	CcSEcCtD
Ponatinib—Dermatitis—Glimepiride—type 2 diabetes mellitus	7.92e-05	0.000551	CcSEcCtD
Ponatinib—Rash—Sitagliptin—type 2 diabetes mellitus	7.9e-05	0.00055	CcSEcCtD
Ponatinib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	7.89e-05	0.00055	CcSEcCtD
Ponatinib—Headache—Glimepiride—type 2 diabetes mellitus	7.87e-05	0.000548	CcSEcCtD
Ponatinib—Cough—Irbesartan—type 2 diabetes mellitus	7.86e-05	0.000547	CcSEcCtD
Ponatinib—Headache—Sitagliptin—type 2 diabetes mellitus	7.85e-05	0.000546	CcSEcCtD
Ponatinib—Anaemia—Losartan—type 2 diabetes mellitus	7.83e-05	0.000545	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	7.79e-05	0.000542	CcSEcCtD
Ponatinib—Oedema—Metformin—type 2 diabetes mellitus	7.79e-05	0.000542	CcSEcCtD
Ponatinib—Hypertension—Irbesartan—type 2 diabetes mellitus	7.77e-05	0.000541	CcSEcCtD
Ponatinib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	7.76e-05	0.00054	CcSEcCtD
Ponatinib—Flushing—Ramipril—type 2 diabetes mellitus	7.75e-05	0.000539	CcSEcCtD
Ponatinib—Infection—Metformin—type 2 diabetes mellitus	7.73e-05	0.000539	CcSEcCtD
Ponatinib—Insomnia—Valsartan—type 2 diabetes mellitus	7.73e-05	0.000538	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	7.7e-05	0.000536	CcSEcCtD
Ponatinib—Paraesthesia—Valsartan—type 2 diabetes mellitus	7.68e-05	0.000535	CcSEcCtD
Ponatinib—Myalgia—Irbesartan—type 2 diabetes mellitus	7.66e-05	0.000534	CcSEcCtD
Ponatinib—Arthralgia—Irbesartan—type 2 diabetes mellitus	7.66e-05	0.000534	CcSEcCtD
Ponatinib—Insomnia—Orlistat—type 2 diabetes mellitus	7.64e-05	0.000532	CcSEcCtD
Ponatinib—Nervous system disorder—Metformin—type 2 diabetes mellitus	7.64e-05	0.000532	CcSEcCtD
Ponatinib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	7.62e-05	0.000531	CcSEcCtD
Ponatinib—Dyspnoea—Valsartan—type 2 diabetes mellitus	7.62e-05	0.000531	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	7.61e-05	0.00053	CcSEcCtD
Ponatinib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	7.61e-05	0.00053	CcSEcCtD
Ponatinib—Paraesthesia—Orlistat—type 2 diabetes mellitus	7.59e-05	0.000528	CcSEcCtD
Ponatinib—Leukopenia—Losartan—type 2 diabetes mellitus	7.58e-05	0.000528	CcSEcCtD
Ponatinib—Skin disorder—Metformin—type 2 diabetes mellitus	7.56e-05	0.000527	CcSEcCtD
Ponatinib—Hyperhidrosis—Metformin—type 2 diabetes mellitus	7.53e-05	0.000524	CcSEcCtD
Ponatinib—Dyspepsia—Valsartan—type 2 diabetes mellitus	7.53e-05	0.000524	CcSEcCtD
Ponatinib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	7.52e-05	0.000524	CcSEcCtD
Ponatinib—Dizziness—Bromocriptine—type 2 diabetes mellitus	7.5e-05	0.000522	CcSEcCtD
Ponatinib—Dry mouth—Irbesartan—type 2 diabetes mellitus	7.5e-05	0.000522	CcSEcCtD
Ponatinib—Nausea—Glimepiride—type 2 diabetes mellitus	7.46e-05	0.00052	CcSEcCtD
Ponatinib—Arrhythmia—Ramipril—type 2 diabetes mellitus	7.46e-05	0.000519	CcSEcCtD
Ponatinib—Nausea—Sitagliptin—type 2 diabetes mellitus	7.44e-05	0.000518	CcSEcCtD
Ponatinib—Dyspepsia—Orlistat—type 2 diabetes mellitus	7.44e-05	0.000518	CcSEcCtD
Ponatinib—Asthenia—Glyburide—type 2 diabetes mellitus	7.44e-05	0.000518	CcSEcCtD
Ponatinib—Decreased appetite—Valsartan—type 2 diabetes mellitus	7.43e-05	0.000518	CcSEcCtD
Ponatinib—Cough—Losartan—type 2 diabetes mellitus	7.39e-05	0.000515	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	7.38e-05	0.000514	CcSEcCtD
Ponatinib—Alopecia—Ramipril—type 2 diabetes mellitus	7.37e-05	0.000514	CcSEcCtD
Ponatinib—Fatigue—Valsartan—type 2 diabetes mellitus	7.37e-05	0.000513	CcSEcCtD
Ponatinib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	7.36e-05	0.000512	CcSEcCtD
Ponatinib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	7.36e-05	0.000512	CcSEcCtD
Ponatinib—Oedema—Irbesartan—type 2 diabetes mellitus	7.35e-05	0.000512	CcSEcCtD
Ponatinib—Decreased appetite—Orlistat—type 2 diabetes mellitus	7.34e-05	0.000511	CcSEcCtD
Ponatinib—Pruritus—Glyburide—type 2 diabetes mellitus	7.33e-05	0.000511	CcSEcCtD
Ponatinib—Mental disorder—Ramipril—type 2 diabetes mellitus	7.31e-05	0.000509	CcSEcCtD
Ponatinib—Constipation—Valsartan—type 2 diabetes mellitus	7.31e-05	0.000509	CcSEcCtD
Ponatinib—Infection—Irbesartan—type 2 diabetes mellitus	7.3e-05	0.000508	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	7.29e-05	0.000508	CcSEcCtD
Ponatinib—Fatigue—Orlistat—type 2 diabetes mellitus	7.28e-05	0.000507	CcSEcCtD
Ponatinib—Malnutrition—Ramipril—type 2 diabetes mellitus	7.26e-05	0.000506	CcSEcCtD
Ponatinib—Erythema—Ramipril—type 2 diabetes mellitus	7.26e-05	0.000506	CcSEcCtD
Ponatinib—Pain—Orlistat—type 2 diabetes mellitus	7.22e-05	0.000503	CcSEcCtD
Ponatinib—Arthralgia—Losartan—type 2 diabetes mellitus	7.21e-05	0.000502	CcSEcCtD
Ponatinib—Myalgia—Losartan—type 2 diabetes mellitus	7.21e-05	0.000502	CcSEcCtD
Ponatinib—Vomiting—Bromocriptine—type 2 diabetes mellitus	7.21e-05	0.000502	CcSEcCtD
Ponatinib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	7.21e-05	0.000502	CcSEcCtD
Ponatinib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	7.19e-05	0.000501	CcSEcCtD
Ponatinib—Rash—Bromocriptine—type 2 diabetes mellitus	7.15e-05	0.000498	CcSEcCtD
Ponatinib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	7.14e-05	0.000497	CcSEcCtD
Ponatinib—Skin disorder—Irbesartan—type 2 diabetes mellitus	7.14e-05	0.000497	CcSEcCtD
Ponatinib—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	7.1e-05	0.000495	CcSEcCtD
Ponatinib—Headache—Bromocriptine—type 2 diabetes mellitus	7.1e-05	0.000495	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	7.09e-05	0.000494	CcSEcCtD
Ponatinib—Diarrhoea—Glyburide—type 2 diabetes mellitus	7.09e-05	0.000494	CcSEcCtD
Ponatinib—Dry mouth—Losartan—type 2 diabetes mellitus	7.05e-05	0.000491	CcSEcCtD
Ponatinib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	6.99e-05	0.000487	CcSEcCtD
Ponatinib—Paraesthesia—Metformin—type 2 diabetes mellitus	6.99e-05	0.000487	CcSEcCtD
Ponatinib—Muscle spasms—Ramipril—type 2 diabetes mellitus	6.98e-05	0.000486	CcSEcCtD
Ponatinib—Dyspnoea—Metformin—type 2 diabetes mellitus	6.94e-05	0.000483	CcSEcCtD
Ponatinib—Oedema—Losartan—type 2 diabetes mellitus	6.91e-05	0.000482	CcSEcCtD
Ponatinib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	6.91e-05	0.000481	CcSEcCtD
Ponatinib—ABCB1—liver—type 2 diabetes mellitus	6.9e-05	0.00121	CbGeAlD
Ponatinib—Infection—Losartan—type 2 diabetes mellitus	6.87e-05	0.000478	CcSEcCtD
Ponatinib—Dyspepsia—Metformin—type 2 diabetes mellitus	6.85e-05	0.000477	CcSEcCtD
Ponatinib—Nervous system disorder—Losartan—type 2 diabetes mellitus	6.78e-05	0.000472	CcSEcCtD
Ponatinib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	6.77e-05	0.000471	CcSEcCtD
Ponatinib—Decreased appetite—Metformin—type 2 diabetes mellitus	6.77e-05	0.000471	CcSEcCtD
Ponatinib—Abdominal pain—Valsartan—type 2 diabetes mellitus	6.76e-05	0.000471	CcSEcCtD
Ponatinib—Nausea—Bromocriptine—type 2 diabetes mellitus	6.73e-05	0.000469	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	6.72e-05	0.000468	CcSEcCtD
Ponatinib—Fatigue—Metformin—type 2 diabetes mellitus	6.71e-05	0.000467	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	6.69e-05	0.000466	CcSEcCtD
Ponatinib—Hyperhidrosis—Losartan—type 2 diabetes mellitus	6.68e-05	0.000465	CcSEcCtD
Ponatinib—Body temperature increased—Orlistat—type 2 diabetes mellitus	6.68e-05	0.000465	CcSEcCtD
Ponatinib—Abdominal pain—Orlistat—type 2 diabetes mellitus	6.68e-05	0.000465	CcSEcCtD
Ponatinib—Asthenia—Gliclazide—type 2 diabetes mellitus	6.68e-05	0.000465	CcSEcCtD
Ponatinib—Constipation—Metformin—type 2 diabetes mellitus	6.66e-05	0.000464	CcSEcCtD
Ponatinib—Paraesthesia—Irbesartan—type 2 diabetes mellitus	6.6e-05	0.000459	CcSEcCtD
Ponatinib—Vomiting—Glyburide—type 2 diabetes mellitus	6.59e-05	0.000459	CcSEcCtD
Ponatinib—Pruritus—Gliclazide—type 2 diabetes mellitus	6.58e-05	0.000458	CcSEcCtD
Ponatinib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	6.55e-05	0.000456	CcSEcCtD
Ponatinib—Rash—Glyburide—type 2 diabetes mellitus	6.53e-05	0.000455	CcSEcCtD
Ponatinib—Dermatitis—Glyburide—type 2 diabetes mellitus	6.53e-05	0.000455	CcSEcCtD
Ponatinib—Leukopenia—Ramipril—type 2 diabetes mellitus	6.5e-05	0.000453	CcSEcCtD
Ponatinib—Headache—Glyburide—type 2 diabetes mellitus	6.49e-05	0.000452	CcSEcCtD
Ponatinib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	6.47e-05	0.00045	CcSEcCtD
Ponatinib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	6.39e-05	0.000445	CcSEcCtD
Ponatinib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	6.37e-05	0.000443	CcSEcCtD
Ponatinib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	6.37e-05	0.000443	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	6.34e-05	0.000442	CcSEcCtD
Ponatinib—Cough—Ramipril—type 2 diabetes mellitus	6.34e-05	0.000441	CcSEcCtD
Ponatinib—Fatigue—Irbesartan—type 2 diabetes mellitus	6.33e-05	0.000441	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	6.3e-05	0.000439	CcSEcCtD
Ponatinib—Pain—Irbesartan—type 2 diabetes mellitus	6.28e-05	0.000438	CcSEcCtD
Ponatinib—Constipation—Irbesartan—type 2 diabetes mellitus	6.28e-05	0.000438	CcSEcCtD
Ponatinib—Insomnia—Losartan—type 2 diabetes mellitus	6.25e-05	0.000436	CcSEcCtD
Ponatinib—Paraesthesia—Losartan—type 2 diabetes mellitus	6.21e-05	0.000432	CcSEcCtD
Ponatinib—Arthralgia—Ramipril—type 2 diabetes mellitus	6.18e-05	0.000431	CcSEcCtD
Ponatinib—Myalgia—Ramipril—type 2 diabetes mellitus	6.18e-05	0.000431	CcSEcCtD
Ponatinib—Dyspnoea—Losartan—type 2 diabetes mellitus	6.16e-05	0.000429	CcSEcCtD
Ponatinib—Nausea—Glyburide—type 2 diabetes mellitus	6.16e-05	0.000429	CcSEcCtD
Ponatinib—Abdominal pain—Metformin—type 2 diabetes mellitus	6.15e-05	0.000429	CcSEcCtD
Ponatinib—Dizziness—Gliclazide—type 2 diabetes mellitus	6.15e-05	0.000429	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	6.14e-05	0.000428	CcSEcCtD
Ponatinib—Asthenia—Valsartan—type 2 diabetes mellitus	6.13e-05	0.000427	CcSEcCtD
Ponatinib—Dyspepsia—Losartan—type 2 diabetes mellitus	6.09e-05	0.000424	CcSEcCtD
Ponatinib—Asthenia—Orlistat—type 2 diabetes mellitus	6.06e-05	0.000422	CcSEcCtD
Ponatinib—Pruritus—Valsartan—type 2 diabetes mellitus	6.05e-05	0.000421	CcSEcCtD
Ponatinib—Dry mouth—Ramipril—type 2 diabetes mellitus	6.05e-05	0.000421	CcSEcCtD
Ponatinib—Decreased appetite—Losartan—type 2 diabetes mellitus	6.01e-05	0.000419	CcSEcCtD
Ponatinib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	6.01e-05	0.000418	CcSEcCtD
Ponatinib—Pruritus—Orlistat—type 2 diabetes mellitus	5.98e-05	0.000416	CcSEcCtD
Ponatinib—Fatigue—Losartan—type 2 diabetes mellitus	5.96e-05	0.000415	CcSEcCtD
Ponatinib—Oedema—Ramipril—type 2 diabetes mellitus	5.93e-05	0.000413	CcSEcCtD
Ponatinib—Vomiting—Gliclazide—type 2 diabetes mellitus	5.92e-05	0.000412	CcSEcCtD
Ponatinib—Pain—Losartan—type 2 diabetes mellitus	5.91e-05	0.000412	CcSEcCtD
Ponatinib—Constipation—Losartan—type 2 diabetes mellitus	5.91e-05	0.000412	CcSEcCtD
Ponatinib—Rash—Gliclazide—type 2 diabetes mellitus	5.87e-05	0.000409	CcSEcCtD
Ponatinib—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.86e-05	0.000408	CcSEcCtD
Ponatinib—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.85e-05	0.000407	CcSEcCtD
Ponatinib—Headache—Gliclazide—type 2 diabetes mellitus	5.83e-05	0.000406	CcSEcCtD
Ponatinib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	5.81e-05	0.000405	CcSEcCtD
Ponatinib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	5.81e-05	0.000404	CcSEcCtD
Ponatinib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	5.81e-05	0.000404	CcSEcCtD
Ponatinib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	5.81e-05	0.000404	CcSEcCtD
Ponatinib—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.78e-05	0.000403	CcSEcCtD
Ponatinib—Skin disorder—Ramipril—type 2 diabetes mellitus	5.76e-05	0.000401	CcSEcCtD
Ponatinib—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	5.73e-05	0.000399	CcSEcCtD
Ponatinib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	5.65e-05	0.000394	CcSEcCtD
Ponatinib—Dizziness—Valsartan—type 2 diabetes mellitus	5.65e-05	0.000394	CcSEcCtD
Ponatinib—Dizziness—Orlistat—type 2 diabetes mellitus	5.59e-05	0.000389	CcSEcCtD
Ponatinib—Asthenia—Metformin—type 2 diabetes mellitus	5.59e-05	0.000389	CcSEcCtD
Ponatinib—Nausea—Gliclazide—type 2 diabetes mellitus	5.53e-05	0.000385	CcSEcCtD
Ponatinib—Pruritus—Metformin—type 2 diabetes mellitus	5.51e-05	0.000384	CcSEcCtD
Ponatinib—Body temperature increased—Losartan—type 2 diabetes mellitus	5.47e-05	0.000381	CcSEcCtD
Ponatinib—Abdominal pain—Losartan—type 2 diabetes mellitus	5.47e-05	0.000381	CcSEcCtD
Ponatinib—Vomiting—Valsartan—type 2 diabetes mellitus	5.44e-05	0.000379	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	5.4e-05	0.000376	CcSEcCtD
Ponatinib—Rash—Valsartan—type 2 diabetes mellitus	5.39e-05	0.000375	CcSEcCtD
Ponatinib—Dermatitis—Valsartan—type 2 diabetes mellitus	5.39e-05	0.000375	CcSEcCtD
Ponatinib—Vomiting—Orlistat—type 2 diabetes mellitus	5.37e-05	0.000374	CcSEcCtD
Ponatinib—Insomnia—Ramipril—type 2 diabetes mellitus	5.36e-05	0.000373	CcSEcCtD
Ponatinib—Headache—Valsartan—type 2 diabetes mellitus	5.36e-05	0.000373	CcSEcCtD
Ponatinib—Diarrhoea—Metformin—type 2 diabetes mellitus	5.33e-05	0.000371	CcSEcCtD
Ponatinib—Rash—Orlistat—type 2 diabetes mellitus	5.33e-05	0.000371	CcSEcCtD
Ponatinib—Paraesthesia—Ramipril—type 2 diabetes mellitus	5.32e-05	0.000371	CcSEcCtD
Ponatinib—Dermatitis—Orlistat—type 2 diabetes mellitus	5.32e-05	0.000371	CcSEcCtD
Ponatinib—Headache—Orlistat—type 2 diabetes mellitus	5.29e-05	0.000369	CcSEcCtD
Ponatinib—Dyspnoea—Ramipril—type 2 diabetes mellitus	5.29e-05	0.000368	CcSEcCtD
Ponatinib—Asthenia—Irbesartan—type 2 diabetes mellitus	5.27e-05	0.000367	CcSEcCtD
Ponatinib—Dyspepsia—Ramipril—type 2 diabetes mellitus	5.22e-05	0.000363	CcSEcCtD
Ponatinib—Pruritus—Irbesartan—type 2 diabetes mellitus	5.2e-05	0.000362	CcSEcCtD
Ponatinib—Decreased appetite—Ramipril—type 2 diabetes mellitus	5.15e-05	0.000359	CcSEcCtD
Ponatinib—Dizziness—Metformin—type 2 diabetes mellitus	5.15e-05	0.000359	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	5.12e-05	0.000356	CcSEcCtD
Ponatinib—Fatigue—Ramipril—type 2 diabetes mellitus	5.11e-05	0.000356	CcSEcCtD
Ponatinib—Nausea—Valsartan—type 2 diabetes mellitus	5.08e-05	0.000354	CcSEcCtD
Ponatinib—Constipation—Ramipril—type 2 diabetes mellitus	5.07e-05	0.000353	CcSEcCtD
Ponatinib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	5.03e-05	0.00035	CcSEcCtD
Ponatinib—Nausea—Orlistat—type 2 diabetes mellitus	5.02e-05	0.000349	CcSEcCtD
Ponatinib—Asthenia—Losartan—type 2 diabetes mellitus	4.96e-05	0.000345	CcSEcCtD
Ponatinib—Vomiting—Metformin—type 2 diabetes mellitus	4.95e-05	0.000345	CcSEcCtD
Ponatinib—Rash—Metformin—type 2 diabetes mellitus	4.91e-05	0.000342	CcSEcCtD
Ponatinib—Dermatitis—Metformin—type 2 diabetes mellitus	4.9e-05	0.000342	CcSEcCtD
Ponatinib—Pruritus—Losartan—type 2 diabetes mellitus	4.89e-05	0.000341	CcSEcCtD
Ponatinib—Headache—Metformin—type 2 diabetes mellitus	4.88e-05	0.00034	CcSEcCtD
Ponatinib—Dizziness—Irbesartan—type 2 diabetes mellitus	4.86e-05	0.000338	CcSEcCtD
Ponatinib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	4.85e-05	0.000338	CcSEcCtD
Ponatinib—Diarrhoea—Losartan—type 2 diabetes mellitus	4.73e-05	0.000329	CcSEcCtD
Ponatinib—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.69e-05	0.000326	CcSEcCtD
Ponatinib—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.69e-05	0.000326	CcSEcCtD
Ponatinib—Vomiting—Irbesartan—type 2 diabetes mellitus	4.67e-05	0.000325	CcSEcCtD
Ponatinib—Rash—Irbesartan—type 2 diabetes mellitus	4.63e-05	0.000323	CcSEcCtD
Ponatinib—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.63e-05	0.000322	CcSEcCtD
Ponatinib—Nausea—Metformin—type 2 diabetes mellitus	4.62e-05	0.000322	CcSEcCtD
Ponatinib—Headache—Irbesartan—type 2 diabetes mellitus	4.6e-05	0.000321	CcSEcCtD
Ponatinib—Dizziness—Losartan—type 2 diabetes mellitus	4.57e-05	0.000318	CcSEcCtD
Ponatinib—Vomiting—Losartan—type 2 diabetes mellitus	4.4e-05	0.000306	CcSEcCtD
Ponatinib—Nausea—Irbesartan—type 2 diabetes mellitus	4.36e-05	0.000304	CcSEcCtD
Ponatinib—Rash—Losartan—type 2 diabetes mellitus	4.36e-05	0.000304	CcSEcCtD
Ponatinib—Dermatitis—Losartan—type 2 diabetes mellitus	4.36e-05	0.000303	CcSEcCtD
Ponatinib—Headache—Losartan—type 2 diabetes mellitus	4.33e-05	0.000302	CcSEcCtD
Ponatinib—Asthenia—Ramipril—type 2 diabetes mellitus	4.25e-05	0.000296	CcSEcCtD
Ponatinib—Pruritus—Ramipril—type 2 diabetes mellitus	4.19e-05	0.000292	CcSEcCtD
Ponatinib—Nausea—Losartan—type 2 diabetes mellitus	4.11e-05	0.000286	CcSEcCtD
Ponatinib—Diarrhoea—Ramipril—type 2 diabetes mellitus	4.06e-05	0.000282	CcSEcCtD
Ponatinib—Dizziness—Ramipril—type 2 diabetes mellitus	3.92e-05	0.000273	CcSEcCtD
Ponatinib—Vomiting—Ramipril—type 2 diabetes mellitus	3.77e-05	0.000263	CcSEcCtD
Ponatinib—Rash—Ramipril—type 2 diabetes mellitus	3.74e-05	0.00026	CcSEcCtD
Ponatinib—Dermatitis—Ramipril—type 2 diabetes mellitus	3.73e-05	0.00026	CcSEcCtD
Ponatinib—Headache—Ramipril—type 2 diabetes mellitus	3.71e-05	0.000259	CcSEcCtD
Ponatinib—Nausea—Ramipril—type 2 diabetes mellitus	3.52e-05	0.000245	CcSEcCtD
Ponatinib—SRC—Innate Immune System—IL6—type 2 diabetes mellitus	1.51e-06	1.13e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.51e-06	1.13e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARA—type 2 diabetes mellitus	1.51e-06	1.13e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTM1—type 2 diabetes mellitus	1.51e-06	1.12e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.5e-06	1.12e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—NOS3—type 2 diabetes mellitus	1.5e-06	1.12e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.5e-06	1.12e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—type 2 diabetes mellitus	1.49e-06	1.12e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RELA—type 2 diabetes mellitus	1.48e-06	1.11e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—type 2 diabetes mellitus	1.48e-06	1.11e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—LPL—type 2 diabetes mellitus	1.48e-06	1.1e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—SRC—type 2 diabetes mellitus	1.48e-06	1.1e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—INS—type 2 diabetes mellitus	1.47e-06	1.1e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	1.46e-06	1.09e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.46e-06	1.09e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—type 2 diabetes mellitus	1.46e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.45e-06	1.08e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	1.45e-06	1.08e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	1.44e-06	1.08e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.44e-06	1.07e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.44e-06	1.07e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	1.44e-06	1.07e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.43e-06	1.07e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	1.43e-06	1.07e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.43e-06	1.06e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.42e-06	1.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.42e-06	1.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.42e-06	1.06e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.42e-06	1.06e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	1.42e-06	1.06e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.42e-06	1.06e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	1.42e-06	1.06e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	1.41e-06	1.05e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	1.41e-06	1.05e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NFKB1—type 2 diabetes mellitus	1.4e-06	1.05e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SRC—type 2 diabetes mellitus	1.4e-06	1.04e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—type 2 diabetes mellitus	1.4e-06	1.04e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.39e-06	1.04e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	1.39e-06	1.04e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	1.39e-06	1.04e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.39e-06	1.03e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—type 2 diabetes mellitus	1.38e-06	1.03e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—type 2 diabetes mellitus	1.38e-06	1.03e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	1.37e-06	1.02e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—type 2 diabetes mellitus	1.37e-06	1.02e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—type 2 diabetes mellitus	1.37e-06	1.02e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—SRC—type 2 diabetes mellitus	1.37e-06	1.02e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.36e-06	1.02e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.36e-06	1.02e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.36e-06	1.02e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.35e-06	1.01e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.35e-06	1.01e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—type 2 diabetes mellitus	1.34e-06	1e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—type 2 diabetes mellitus	1.34e-06	1e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.34e-06	1e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.34e-06	9.99e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.34e-06	9.97e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.34e-06	9.97e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.33e-06	9.96e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	1.33e-06	9.96e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	1.33e-06	9.94e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	1.33e-06	9.91e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.33e-06	9.89e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SRC—type 2 diabetes mellitus	1.32e-06	9.87e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.31e-06	9.8e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	1.31e-06	9.78e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.31e-06	9.77e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	1.31e-06	9.75e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—INS—type 2 diabetes mellitus	1.3e-06	9.74e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.3e-06	9.71e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.3e-06	9.71e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.3e-06	9.71e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—type 2 diabetes mellitus	1.3e-06	9.67e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.29e-06	9.65e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.29e-06	9.64e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.29e-06	9.64e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.29e-06	9.63e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.29e-06	9.62e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.29e-06	9.61e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.29e-06	9.59e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.28e-06	9.58e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—type 2 diabetes mellitus	1.28e-06	9.52e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—type 2 diabetes mellitus	1.27e-06	9.51e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	1.27e-06	9.49e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—type 2 diabetes mellitus	1.27e-06	9.49e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.27e-06	9.49e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—type 2 diabetes mellitus	1.27e-06	9.48e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.27e-06	9.48e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	1.27e-06	9.45e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.26e-06	9.44e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—type 2 diabetes mellitus	1.26e-06	9.42e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.26e-06	9.42e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.26e-06	9.42e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.26e-06	9.41e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.26e-06	9.38e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.26e-06	9.37e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.25e-06	9.34e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.25e-06	9.32e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	1.25e-06	9.31e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.25e-06	9.3e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	1.24e-06	9.29e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	1.24e-06	9.25e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—type 2 diabetes mellitus	1.24e-06	9.25e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.24e-06	9.23e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	1.23e-06	9.15e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.22e-06	9.14e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.22e-06	9.14e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	1.22e-06	9.13e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—type 2 diabetes mellitus	1.22e-06	9.11e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RELA—type 2 diabetes mellitus	1.22e-06	9.08e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—type 2 diabetes mellitus	1.22e-06	9.07e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.21e-06	9.06e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—type 2 diabetes mellitus	1.21e-06	9.06e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.21e-06	9.03e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—type 2 diabetes mellitus	1.21e-06	9.03e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.2e-06	8.94e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—type 2 diabetes mellitus	1.2e-06	8.93e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.19e-06	8.87e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.19e-06	8.84e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.18e-06	8.84e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.18e-06	8.82e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—type 2 diabetes mellitus	1.18e-06	8.78e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—type 2 diabetes mellitus	1.17e-06	8.76e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.17e-06	8.71e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.17e-06	8.71e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.17e-06	8.71e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SRC—type 2 diabetes mellitus	1.17e-06	8.7e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.16e-06	8.67e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.16e-06	8.66e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.16e-06	8.65e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.15e-06	8.61e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—type 2 diabetes mellitus	1.15e-06	8.56e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.15e-06	8.55e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.14e-06	8.54e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.14e-06	8.54e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.14e-06	8.5e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.14e-06	8.5e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.14e-06	8.48e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.14e-06	8.47e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	1.12e-06	8.37e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—type 2 diabetes mellitus	1.12e-06	8.36e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.12e-06	8.35e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—type 2 diabetes mellitus	1.12e-06	8.33e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.11e-06	8.29e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.1e-06	8.23e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.1e-06	8.19e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.09e-06	8.16e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.08e-06	8.09e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.08e-06	8.06e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—type 2 diabetes mellitus	1.08e-06	8.06e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	1.08e-06	8.06e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RELA—type 2 diabetes mellitus	1.08e-06	8.04e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.07e-06	8.01e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	1.07e-06	8.01e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	1.07e-06	8.01e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.07e-06	7.97e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.07e-06	7.97e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	1.06e-06	7.91e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—type 2 diabetes mellitus	1.06e-06	7.9e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.06e-06	7.88e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.06e-06	7.88e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.04e-06	7.78e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—type 2 diabetes mellitus	1.04e-06	7.77e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.04e-06	7.75e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.04e-06	7.74e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.03e-06	7.66e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.02e-06	7.63e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.02e-06	7.62e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.02e-06	7.6e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.01e-06	7.55e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.01e-06	7.55e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.01e-06	7.51e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—type 2 diabetes mellitus	9.96e-07	7.43e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	9.81e-07	7.32e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	9.71e-07	7.25e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.71e-07	7.25e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—type 2 diabetes mellitus	9.58e-07	7.15e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SRC—type 2 diabetes mellitus	9.56e-07	7.13e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	9.41e-07	7.02e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—type 2 diabetes mellitus	9.41e-07	7.02e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.31e-07	6.95e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	9.29e-07	6.93e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	9.29e-07	6.93e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	9.23e-07	6.89e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—type 2 diabetes mellitus	9.2e-07	6.86e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—type 2 diabetes mellitus	9.19e-07	6.86e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.18e-07	6.85e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.08e-07	6.78e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—type 2 diabetes mellitus	8.93e-07	6.66e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—type 2 diabetes mellitus	8.91e-07	6.65e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	8.87e-07	6.62e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.84e-07	6.6e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—type 2 diabetes mellitus	8.82e-07	6.58e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	8.72e-07	6.51e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	8.72e-07	6.51e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	8.7e-07	6.49e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	8.68e-07	6.48e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.68e-07	6.48e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	8.57e-07	6.39e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.55e-07	6.38e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	8.5e-07	6.34e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—type 2 diabetes mellitus	8.48e-07	6.33e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	8.46e-07	6.31e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.38e-07	6.25e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	8.32e-07	6.21e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.24e-07	6.15e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.24e-07	6.15e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.22e-07	6.13e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—type 2 diabetes mellitus	8.14e-07	6.07e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—type 2 diabetes mellitus	8.13e-07	6.07e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	8.09e-07	6.04e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	8.09e-07	6.04e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	8.09e-07	6.04e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	7.97e-07	5.95e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	7.94e-07	5.93e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—type 2 diabetes mellitus	7.86e-07	5.86e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	7.77e-07	5.8e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	7.75e-07	5.78e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	7.63e-07	5.69e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	7.63e-07	5.69e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.56e-07	5.65e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	7.55e-07	5.63e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—type 2 diabetes mellitus	7.51e-07	5.6e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	7.45e-07	5.56e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.42e-07	5.54e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	7.4e-07	5.52e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.25e-07	5.41e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	7.15e-07	5.34e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	7.02e-07	5.23e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	6.98e-07	5.21e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	6.88e-07	5.14e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	6.79e-07	5.07e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	6.68e-07	4.99e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	6.66e-07	4.97e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	6.58e-07	4.91e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—type 2 diabetes mellitus	6.44e-07	4.81e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.94e-07	4.43e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	5.8e-07	4.33e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—type 2 diabetes mellitus	5.7e-07	4.25e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	5.69e-07	4.24e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.26e-07	3.92e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	5.21e-07	3.89e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	4.99e-07	3.72e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	4.99e-07	3.72e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	4.93e-07	3.68e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	4.56e-07	3.4e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	4.27e-07	3.19e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	3.72e-07	2.78e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	3.51e-07	2.62e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	2.29e-07	1.71e-06	CbGpPWpGaD
